.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,525,060

« Back to Dashboard
Patent 6,525,060 protects BRILINTA and is included in one NDA. There have been two Paragraph IV challenges on Brilinta.

This patent has seventy-four patent family members in thirty-three countries.

Summary for Patent: 6,525,060

Title: Triazolo(4,5-d)pyrimidine compounds
Abstract:Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: ##STR1## wherein R, X and R.sup.1 through R.sup.3 are as defined in the specification.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: Astrazeneca UK Limited (London, GB)
Application Number:09/508,195
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 2nd percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo6,525,060► subscribeYY REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo6,525,060► subscribeYY TREATMENT OF STROKE
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo6,525,060► subscribeYY REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,525,060

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9804211Dec 04, 1998
Sweden9901271Apr 09, 1999
PCT Information
PCT FiledDecember 02, 1999PCT Application Number:PCT/SE99/02256
PCT Publication Date:June 15, 2000PCT Publication Number: WO00/34283

Non-Orange Book Patents for Patent: 6,525,060

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,250,419Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition► subscribe
6,974,868 Compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,525,060

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina023920► subscribe
Argentina058967► subscribe
Argentina072756► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc